Xilio Therapeutics, Inc. (XLO) Financials

XLO Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 154.3 million 82.0 million
March 31, 2026 163.5 million 90.9 million
Dec. 31, 2025 154.7 million 119.4 million
Sept. 30, 2025 133.7 million 141.8 million

XLO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -18.8 million 1.6 million
March 31, 2026 -22.9 million 2.2 million
Dec. 31, 2025 -2.1 million 2.9 million
Sept. 30, 2025 -17.5 million 1.1 million

XLO Net Income

No data available :(

XLO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 136.0 million - 6.3 million
March 31, 2026 150.3 million 5.3 million 1.4 million
Dec. 31, 2025 137.5 million - 7.0 million
Sept. 30, 2025 103.8 million - 7.3 million

XLO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 19.4 million
March 31, 2026 163.5 million
Dec. 31, 2025 83.6 million
Sept. 30, 2025 10.3 million

XLO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 19000 14.6 million 7.6 million -
March 31, 2026 556000 19.8 million 6.6 million -344000
Dec. 31, 2025 95000 18.1 million 7.4 million -
Sept. 30, 2025 - 14.3 million 6.7 million -

XLO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 18.7 million -
March 31, 2026 12.6 million 344000
Dec. 31, 2025 13.7 million 323000
Sept. 30, 2025 19.1 million 340000

XLO

Price: $9.50

52 week price:
6.47
12.74

Earnings Per Share: -0.32 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 18100

Market Capitalization: 60.3 million

Links: